Zydus receives final approval from the USFDA for Tranexamic Acid Injection

Zydus Cadila has received the final approval from the USFDA to market Tranexamic Acid Injection, 1000 mg/10 mL (100 mg/mL) Single dose Vial. Tranexamic Acid Injection belongs to the class of medications called antifibrinolytic agents. This medication is used to prevent or reduce bleeding in patients with haemophilia undergoing tooth extraction and will be produced at the group's formulations manufacturing facility at Moraiya, in Ahmedabad.

The group now has more than 130 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.544.25 as compared to the previous close of Rs. 524.95. The total number of shares traded during the day was 110480 in over 2674 trades.

The stock hit an intraday high of Rs. 549.55 and intraday low of 527.35. The net turnover during the day was Rs. 59462599.

Source : Equity Bulls

Keywords